This is the authors' abstract. We don't add key points for this paper.
Experimental investigations and serendipitous clinical reports had indicated that hematopoietic stem cell transplantation (HSCT) could represent a new powerful procedure for treating severe autoimmune diseases (SADs). Although the therapeutic potential of allogeneic transplantation appeared theoretically potentially curative, the almost paradoxical results by van Bekkum and his group indicated that the autologous procedure also had outstanding therapeutic potential. The European and American experience includes by now an estimated number of autologous transplants for SADs of well over 1000 cases. The December 2008 issue of Autoimmunity contains the most recent information about the various autoimmune diseases treated with autologous and allogeneic HSCT. This perspective, rather than reporting on already published clinical trials, focuses on the main questions connected with autologous ASCT – that is, its safety, its currently explored advantages and disadvantages versus the best available nontransplant pr...
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Alberto M. Marmont (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: